Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company
16 déc. 2019 11h11 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Dec. 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune", “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a...
Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change
28 oct. 2019 09h30 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical...
Immune Therapeutics, Inc. Announces Advisory Board Appointments
22 oct. 2019 11h03 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company...
Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today
26 sept. 2019 09h00 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors
23 sept. 2019 09h30 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation...
Immune Therapeutics Revises and Resends Proxy Statement
10 sept. 2019 09h30 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics, Inc. Provides Shareholder Update on 14A
15 mai 2019 09h36 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics welcomes Kevin Phelps to Board of Directors
09 janv. 2019 13h44 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune Therapeutics”, “IMUN” or the “Company”), a late stage clinical biopharmaceutical...
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine
13 déc. 2018 10h24 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors
06 sept. 2018 09h30 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation...